Nature Communications (Mar 2020)

A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma

  • Li Ren Kong,
  • Nur Afiqah Binte Mohamed Salleh,
  • Richard Weijie Ong,
  • Tuan Zea Tan,
  • Nicholas L. Syn,
  • Robby Miguel Goh,
  • Chee Wai Fhu,
  • Daniel S. W. Tan,
  • N. Gopalakrishna Iyer,
  • Srinivasaraghavan Kannan,
  • Chandra S. Verma,
  • Yaw Chyn Lim,
  • Ross Soo,
  • Jingshan Ho,
  • Yiqing Huang,
  • Joline S. J. Lim,
  • Benedict Junrong Yan,
  • Min En Nga,
  • Seng Gee Lim,
  • H. Phillip Koeffler,
  • Soo Chin Lee,
  • Dennis Kappei,
  • Huynh The Hung,
  • Boon Cher Goh

DOI
https://doi.org/10.1038/s41467-020-15318-5
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 14

Abstract

Read online

The MET receptor is frequently activated in cancer. Here, the authors show that in head and neck and lung squamous carcinoma, a polymorphic MET variant enhances binding to HER2, resulting in activation of HER2 signalling and progression of the cancers.